Laura Ruth Alder

Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text Cite

Assessing the impact of PCSK9 inhibition in small cell lung cancer with novel DLL3-targeted bispecific T-cell engager therapy.

Conference Journal of Clinical Oncology · June 1, 2026 e20135Background: B-specific T-cell engagers (BiTEs) such as tarlatamab, have improved upon the efficacy and durability of response in small cell lung cancer (SCLC). However, an unmet need remains due to the known “immune-cold” microenvironment and immune ... Full text Cite

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite

ctDNA detection in patients with brain metastases arising from solid tumors

Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2023 Link to item Cite

ctDNA detection in patients with brain metastases arising from solid tumors.

Conference Journal of Clinical Oncology · June 1, 2023 2027 Background: While circulating tumor DNA (ctDNA) is a routine tool for therapeutics in metastatic solid tumors, data in those with stable and active brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA ... Full text Cite

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.

Conference Breast Cancer Res Treat · January 2023 PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never bee ... Full text Link to item Cite

Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd).

Conference CANCER RESEARCH · June 15, 2022 Link to item Cite

Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd)

Conference CANCER RESEARCH · June 15, 2022 Link to item Cite